Under construction – not a live service
Sign in
Taking people in PakistanEarly phase 1

Comparing apremilast and methotrexate for moderate to severe plaque psoriasis

Compares apremilast with methotrexate in adults with chronic plaque psoriasis.

Plain-language title generated from the registry record
Registry title: To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital

Key facts

Where
Peshawar, PakistanSee the site
Phase
Early phase 1

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT07337434, who can take part

Where in Pakistan

  • MTI-HMC PeshawarPeshawar, PakistanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Syeda Sana Zaman
Trial code
NCT07337434
Record updated
13 January 2026
Original description
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.Read full original descriptionShow less

Comparison of Efficacy of Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis

This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.

Inclusion: Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.

Exclusion: Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs.

ClinicalTrials.gov NCT07337434